CRYOMEDICAL SCIENCES INC
SC 13G, 1999-02-01
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Previous: BERNSTEIN SANFORD C FUND INC, 497J, 1999-02-01
Next: MSDW MUNICIPAL INCOME OPPORTUNITIES TRUST, N-30D, 1999-02-01




                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C.  20549
                                                     

                                  SCHEDULE 13G
                                 (Rule 13d-102)

                          INFORMATION TO BE INCLUDED IN
STATEMENTS FILED PURSUANT TO 
                    RULE 13d-1(b), (c) AND (d) AND AMENDMENTS
THERETO FILED PURSUANT TO 
                                  RULE 13d-2(b)

                               (Amendment No. _)*

                           CRYOMEDICAL SCIENCES, INC.                           
                                (Name of Issuer)

                     COMMON STOCK, PAR VALUE $.001 PER SHARE                    
                         (Title of Class of Securities)

                                    229049         
                                 (CUSIP Number)
                                                  

                                December 16, 1998                               
              (Date of Event which Requires Filing this Statement)

Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:

          [ ]       Rule 13d-1(b)
          [X]       Rule 13d-1(c)
          [ ]       Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to
the subject class of securities, and for any subsequent
amendment containing information which would alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover
page shall not be deemed to be "filed" for the purpose of
Section 18 of the Securities Exchange Act of 1934 ("Act")
or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act
(however, see the Notes).

                        (Continued on following page(s))



<TABLE>

CUSIP No. 229049                                            13G
<S>
 1<PAGE>
Name of Reporting Persons
John G. Baust, Ph.D. 

I.R.S. Identification Nos. of Above Persons (Entities Only)           
C
<PAGE>
 2Check the Appropriate Box if a Member of a Group*                                 
                                        (a)   [ ]
                                        (b)   [ ] <PAGE>
 
<C>3<PAGE>
SEC Use Only
<PAGE>
<C> 4<PAGE>
Citizenship or Place of Organization
United States                                                                                                                  
<PAGE>

      Number of
       Shares
    Beneficially
      Owned By 
        Each
      Reporting
       Person
        With<PAGE>
5Sole Voting Power
                                        2,560,000                                                                             
 <PAGE>
 6Shared Voting Power
                                        --      <PAGE>
 7Sole Dispositive Power
                                        2,560,000                                                                             
 <PAGE>
 8Shared Dispositive Power 
                                        --     <PAGE>
 
<C>9<PAGE>
Aggregate Amount Beneficially Owned By Each Reporting Person
  2,560,000<PAGE>
<C>10<PAGE>
Check Box if the Aggregate Amount in Row (9) excludes 
Certain Shares*                                    [ ]    
<PAGE>
11Percent of Class Represented by Amount in Row (9)
 7.1% <PAGE>
12Type of Reporting Person*
  IN
                                                                 
                    *SEE INSTRUCTIONS BEFORE FILLING OUT!

</TABLE>

<PAGE>
Item 1(a).          Name of Issuer:
                    
                    Cryomedical Sciences, Inc.                    
                                             
Item 1(b).          Address of Issuer's Principal Executive
Offices:
                    
                    1300 Piccard Drive, Suite 102, Rockville,
MD 20850                                  

Item 2(a).          Name of Person Filing:
                    
                    John G. Baust, Ph.D.

Item 2(b).          Address of Principal Business Office or, if
None, Residence:
                    
                    1300 Piccard Drive
                    Suite 102
                    Rockville, MD  20850

Item 2(c).          Citizenship:

                    United States
                                        
Item 2(d).          Title of Class of Securities:
                    
                    Common Stock, par value $.001 per share
("Common Stock")                    

Item 2(e).          CUSIP Number:
                    
                      229049                                           
                                                

Item 3.             If This Statement is Filed Pursuant to
                    Rule 13d-1(b), or 13d-2(b) or (c), Check
                    Whether the Person Filing is a:
               
     (a)    [ ]   Broker or dealer registered under Section 15
of the Exchange Act.
     (b)    [ ]   Bank as defined in Section 3(a)(6) of the
Exchange Act.
     (c)    [ ]   Insurance company as defined in Section
3(a)(19) of the Exchange Act.
     (d)    [ ]   Investment company registered under Section
8 of the Investment Company Act.                            
     (e)    [ ]   An investment adviser in accordance with
Rule 13d-1(b)(l)(ii)(E).
     (f)    [ ]   An employee benefit plan or endowment fund
in accordance with Rule 13d-1(b)(l)(ii)(F).                           
(g)       [
    A parent holding company or control person in
accordance with Rule 13d-1(b)(l)(ii)(G).
     (h)    [ ]   A savings association as defined in Section
3(b) of the Federal Deposit Insurance Act.
     (i)    [ ]   A church plan that is excluded from the
definition of an investment company under Section
                  3(c)(14) of the Investment Company Act.     
                                                        
     (j)    [ ]   Group, in accordance with Rule 13d-
l(b)(l)(ii)(J).
     
If this statement is filed pursuant to Rule 13d-1(c), check
this box [X].

Item 4.     Ownership.

     (a)       Amount beneficially owned:

               2,560,000 shares of Common Stock of
               Cryomedical Sciences, Inc., comprised of (i)
               20,000 shares of Common Stock, and (ii) Non-
               Incentive Stock Options and warrants to
               purchase 2,540,000 shares of Common Stock.  
                                                                          
                                                             
     (b)       Percent of class:

               7.1%

     (c)       Number of shares as to which such person has:

     (i)       Sole power to vote or to direct the vote: 
               2,560,000 shares

     (ii)      Shared power to vote or to direct the vote: 
None.                                                 
     (iii)     Sole power to dispose or to direct the
               disposition of:  2,560,000 shares

     (iv)      Shared power to dispose or to direct the
               disposition of:  None.

Item 5.     Ownership of Five Percent of a Class.

     If this statement is being filed to report the fact that as
of the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of
securities, check the following [    ].

Item 6.     Ownership of More than Five Percent on Behalf
of Another Person.

     None.

Item 7.     Identification and Classification of the
Subsidiary Which Acquired the Security
            Being Reported on by the Parent Holding
Company.

     None.

Item 8.     Identification and Classification of Members of
the Group.

     Not Applicable.         

Item 9.     Notice of Dissolution of Group.
     
     Not Applicable.

Item 10.  Certifications.

     By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above were
not acquired and are not held for the purpose of or with the
effect of changing or influencing the control of the issuer
of the securities and were not acquired and are not held in
connection with or as a participant in any transaction
having that purpose or effect.

<PAGE>
                                    SIGNATURE

     After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information set
forth in this statement is true, complete and correct.


Dated:  January 19, 1999


 /s/ John G. Baust                             
John G. Baust, Ph.D.                                        

                                                                               
       


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission